Business Wire

Kirin to Release “Slow Drink(R)” Advertisements Promoting Responsible Drinking in Pursuit of Zero Harmful Drinking During the Holiday Season

10.12.2019 12:30:00 EET | Business Wire | Press release

Share

Kirin Holdings Company, Limited (TOKYO:2503) (President and CEO: Yoshinori Isozaki) plans to begin running advertisements promoting responsible drinking on Twitter (Japanese version) starting Friday, December 6, ahead of the peak season for New Year gatherings. The aim of the ads is to prevent the binge drinking, speed drinking, and other dangerous modes of consuming alcohol often observed at these events, and to promote and encourage responsible drinking.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005439/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IMAGE(1) (Graphic: Business Wire)

The Company unveiled the Kirin Group CSV1 Purpose, which provides guidelines for creating shared value with society and promoting sustainable growth, and serves as long-term, non-financial targets incorporated into the Kirin Group Vision 2027, which represents the Group’s long-term management vision.

The ad campaign is part of our efforts to play a leading role as a responsible alcohol producer as called for in the CSV Purpose.

1CSV: Creating Shared Value. The premise is about creating value that can be shared with customers and society.

The number of people transported emergently to hospitals for acute alcohol poisoning is increasing each year;2 roughly half of those people are in their 20s. The advertisements emphasize the life-threatening danger of binge drinking and other harmful modes of consuming alcohol, and promote responsible drinking namely to people in their 20s who have little experience with alcohol. The ads also communicate the importance of responsible drinking to fulfill the Company’s social responsibility as a manufacturer and seller of alcoholic beverages.

2According to investigations by the fire departments of Tokyo, Osaka, and Nagoya

The Company also plans to stream subtitled English versions of the advertisements with the aim of sharing the message with the world to address the global social issue of harmful alcohol consumption.

YouTube release of subtitled English version: Link: https://youtu.be/0ORj-ZxJdGs
Title: SLOW DRINK (I was just going a little too fast) English version

The Company is proposing “Slow Drink(R)” as a new method of drinking in which people take a relaxed approach to consuming alcohol: being smart and keeping the situation pleasant by drinking in moderation while enjoying good food and conversation with others.

We have created an official logo for “Slow Drink(R)”, and intend to promote new values for alcohol as part of the public education campaign for responsible drinking we are undertaking as an alcohol producer.

In the business environment in which the Kirin Group operates, companies are under increasing pressure to tackle social issues, which include health problems caused by harmful drinking.

We are committed to promoting zero harmful drinking and ensuring that people will continue to enjoy a responsible drinking culture for generations to come.

The Kirin Group is committed to its role as a responsible alcohol producer and addressing the three key social issues: “health and well-being,” “community engagement,” and “the environment.” By fulfilling these commitments, the Group can bring joy to society and a brighter future to our customers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press inquiries, contact:
Corporate Communications Department, Kirin Holdings Co., Ltd.
Tel +81-3-6837-7028

For consumer inquiries, call:
Customer Service, Kirin Holdings Co., Ltd. at 0120-770-502 (toll-free if called from within Japan)
Email address: izawa@ccpr.jp (Ryo Izawa)
Kirin Website: https://www.kirin.co.jp (Images available for download)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye